Chinese language Covid vaccine promising: Examine


Beijing, October 16

One of China’s leading COVID-19 vaccine candidates, called BBIBP-CorV, was shown to be safe and elicited immune response in a small early-phase human trial, researchers said on Friday.

Safe and elicits immune response

  • BBIBP-CorV was shown to be safe and elicited immune response in a small early-phase human trial, researchers said on Friday.

  • A previous clinical trial reported similar results for a different vaccine that is also based on inactivated whole SARS-CoV-2 virus, but in that study the vaccine was only tested in people aged under 60 years.

A previous clinical trial reported similar results for a different vaccine that is also based on inactivated whole SARS-CoV-2 virus, but in that study the vaccine was only tested in people aged under 60 years.

The latest study, published in The Lancet Infectious Diseases journal, included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients.

Participants aged 60 and over were slower to respond, taking 42 days before antibodies were detected in all recipients compared with 28 days for participants aged 18-59, the researchers said.

Antibody levels were also lower in those aged 60-80 years compared with those aged 18-59, they said.

The BBIBP-CorV vaccine used in the study is based on a sample of the virus that was isolated from a patient in China.

Stocks of the virus were grown in the lab using cell lines and then inactivated using a chemical called beta-proprionolactone. — PTI



Be the first to comment on "Chinese language Covid vaccine promising: Examine"

Leave a comment

Your email address will not be published.


*